Resverlogix Corp. (RVXCF)
Resverlogix Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $0.07, up 0.00% on the session, giving a market capitalisation of $22.2M. On trailing twelve-month figures it carries a trailing P/E of -2.70, a net margin of 0.0%. Its beta of 1.05 implies it has historically moved more than the broad market.
Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials. This investigational treatment aims to address a spectrum of serious ailments, including cardiovascular disease, diabetes mellitus, chronic and end-stage kidney disease, and neurodegenerative disorders. Furthermore, Resverlogix has established a collaboration with Eversana Life Science Services, LLC. This alliance is geared towards supporting the forthcoming commercial introduction of apabetalone as a treatment for COVID-19 in both the United States and Canada. The company's operations are based out of Calgary, Canada.
Resverlogix Corp. is most often compared with the following Healthcare names: